These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23775877)

  • 1. Placebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state.
    te Beek ET; Tatosian D; Majumdar A; Selverian D; Klaassen ES; Petty KJ; Gargano C; van Dyck K; McCrea J; Murphy G; van Gerven JM
    J Clin Pharmacol; 2013 Aug; 53(8):846-56. PubMed ID: 23775877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state.
    te Beek ET; Zoethout RW; Bani MS; Andorn A; Iavarone L; Klaassen ES; Fina P; van Gerven JM
    J Psychopharmacol; 2012 Feb; 26(2):303-14. PubMed ID: 22219221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.
    te Beek ET; Hay JL; Bullman JN; Burgess C; Nahon KJ; Klaassen ES; Gray FA; van Gerven JM
    Br J Clin Pharmacol; 2013 May; 75(5):1328-39. PubMed ID: 23067311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.
    Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1681-7. PubMed ID: 19648218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.
    Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1671-9. PubMed ID: 20142308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.
    Barbanoj MJ; García-Gea C; Antonijoan R; Izquierdo I; Donado E; Pérez I; Solans A; Jané F
    Hum Psychopharmacol; 2006 Jan; 21(1):13-26. PubMed ID: 16389668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.
    Liem-Moolenaar M; Gray FA; de Visser SJ; Franson KL; Schoemaker RC; Schmitt JA; Cohen AF; van Gerven JM
    J Psychopharmacol; 2010 Jan; 24(1):73-82. PubMed ID: 18755817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant.
    Jacob D; Busciglio I; Burton D; Halawi H; Oduyebo I; Rhoten D; Ryks M; Harmsen WS; Camilleri M
    Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G505-G510. PubMed ID: 28814387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of a neurokinin-1 receptor antagonist (aprepitant) on gastric sensorimotor function in healthy volunteers.
    Ang D; Pauwels A; Akyuz F; Vos R; Tack J
    Neurogastroenterol Motil; 2013 Dec; 25(12):e830-8. PubMed ID: 23991829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.
    Walsh SL; Heilig M; Nuzzo PA; Henderson P; Lofwall MR
    Addict Biol; 2013 Mar; 18(2):332-43. PubMed ID: 22260216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans.
    Hoch M; Hay JL; Hoever P; de Kam ML; te Beek ET; van Gerven JM; Dingemanse J
    Eur Neuropsychopharmacol; 2013 Feb; 23(2):107-17. PubMed ID: 22658401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor.
    Rosenzweig P; Patat A; Zieleniuk I; Cimarosti I; Allain H; Gandon JM
    Clin Pharmacol Ther; 1998 Aug; 64(2):211-22. PubMed ID: 9728902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials.
    García-Gea C; Martínez J; Ballester MR; Gich I; Valiente R; Antonijoan RM
    Hum Psychopharmacol; 2014 Mar; 29(2):120-32. PubMed ID: 24395298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.
    Majumdar AK; Howard L; Goldberg MR; Hickey L; Constanzer M; Rothenberg PL; Crumley TM; Panebianco D; Bradstreet TE; Bergman AJ; Waldman SA; Greenberg HE; Butler K; Knops A; De Lepeleire I; Michiels N; Petty KJ
    J Clin Pharmacol; 2006 Mar; 46(3):291-300. PubMed ID: 16490805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NK1 receptor antagonist aprepitant attenuates NK1 agonist-induced scratching behaviour in the gerbil after intra-dermal, topical or oral administration.
    Costantini VJ; Corsi M; Dünstl G; Bettelini L; Zonzini L; Gerrard P
    Exp Dermatol; 2015 Apr; 24(4):312-4. PubMed ID: 25650546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central nervous system effects of haloperidol on THC in healthy male volunteers.
    Liem-Moolenaar M; te Beek ET; de Kam ML; Franson KL; Kahn RS; Hijman R; Touw D; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1697-708. PubMed ID: 20142302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers.
    Dumont GJ; Schoemaker RC; Touw DJ; Sweep FC; Buitelaar JK; van Gerven JM; Verkes RJ
    J Psychopharmacol; 2010 Feb; 24(2):155-64. PubMed ID: 19164498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
    Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
    J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers.
    Hallam KT; Olver JS; McGrath C; Norman TR
    Hum Psychopharmacol; 2003 Dec; 18(8):619-25. PubMed ID: 14696021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neurokinin-1 receptor antagonist aprepitant in co-morbid alcohol dependence and posttraumatic stress disorder: a human experimental study.
    Kwako LE; George DT; Schwandt ML; Spagnolo PA; Momenan R; Hommer DW; Diamond CA; Sinha R; Shaham Y; Heilig M
    Psychopharmacology (Berl); 2015 Jan; 232(1):295-304. PubMed ID: 25030801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.